The antibody discovery group wishes to appoint a Postdoctoral Research Associate with experience in cancer immunology/immunotherapy, antibody engineering or equivalent, immune/antibody functional assays and in vivo cancer models, to join its established Cancer Antibody Discovery & Immunotherapy Group research programme. This post, focused on developing novel IgE-based cancer therapeutics and evaluating candidates for commercialization, is one of two funded by a KCL spinout company, Epsilogen Ltd. and integrated into the academic team’s translational research activities, led by Prof. Sophia Karagiannis, who is the founder scientist of Epsilogen Ltd.
The postholder will conduct antibody engineering, in vivo and in vitro/ex vivo antibody functional studies, working closely with the appointed Postdoctoral Research Fellow, and liaising with academic researchers, company staff and collaborators. The programme is conducted to specific deliverables and strict deadlines. Therefore, the position will suit a highly motivated and focused team player, with strong communication and collaborative skills.
This post will be offered on a fixed-term contract until 15th July 2022.
This is a full-time post.
The selection process will include a panel interview, an assessment, a presentation.